Jan-Otto
- Updated follow-up data from a phase 3 trial found that AstraZeneca’s (NASDAQ:AZN) Imfinzi (durvalumab) + chemotherapy led to long-term overall survival at three years in those with advanced biliary tract cancer.
- With a median follow-up of 41.3 months, those on Imfinzi + chemo saw their death risk reduced by 26% versus chemo alone.
- Median overall survival for the combination was 12.9 months compared to 11.3 months for chemo alone. Also, at three years, 14.6% of those on the Imfinzi regimen were alive compared to 6.9% on just chemo.
- Results will be presented April 18 at the 2024 Cholangiocarcinoma Foundation Conference in Salt Lake City, Utah.